JP2016513968A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513968A5 JP2016513968A5 JP2016501273A JP2016501273A JP2016513968A5 JP 2016513968 A5 JP2016513968 A5 JP 2016513968A5 JP 2016501273 A JP2016501273 A JP 2016501273A JP 2016501273 A JP2016501273 A JP 2016501273A JP 2016513968 A5 JP2016513968 A5 JP 2016513968A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- ogt
- polynucleotide
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000003729 nucleotide group Chemical group 0.000 claims 29
- 239000002773 nucleotide Substances 0.000 claims 27
- 108091033319 polynucleotide Proteins 0.000 claims 25
- 239000002157 polynucleotide Substances 0.000 claims 25
- 102000040430 polynucleotide Human genes 0.000 claims 25
- 239000000203 mixture Substances 0.000 claims 15
- 230000000295 complement effect Effects 0.000 claims 12
- 206010052428 Wound Diseases 0.000 claims 9
- 208000027418 Wounds and injury Diseases 0.000 claims 9
- 230000000692 anti-sense effect Effects 0.000 claims 7
- 239000012634 fragment Substances 0.000 claims 7
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 4
- 108091027967 Small hairpin RNA Proteins 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
- 230000001419 dependent effect Effects 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 239000011248 coating agent Substances 0.000 claims 2
- 238000000576 coating method Methods 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000499 gel Substances 0.000 claims 2
- 239000008103 glucose Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 229940046166 oligodeoxynucleotide Drugs 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940072056 alginate Drugs 0.000 claims 1
- 235000010443 alginic acid Nutrition 0.000 claims 1
- 229920000615 alginic acid Polymers 0.000 claims 1
- 239000001768 carboxy methyl cellulose Substances 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000013265 extended release Methods 0.000 claims 1
- 239000006260 foam Substances 0.000 claims 1
- 239000000017 hydrogel Substances 0.000 claims 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229920001992 poloxamer 407 Polymers 0.000 claims 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims 1
- 239000007921 spray Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775937P | 2013-03-11 | 2013-03-11 | |
| US61/775,937 | 2013-03-11 | ||
| PCT/US2014/023525 WO2014164805A1 (en) | 2013-03-11 | 2014-03-11 | Compositions and methods for targeting o-linked n-acetylglucosamine transferase and promoting wound healing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513968A JP2016513968A (ja) | 2016-05-19 |
| JP2016513968A5 true JP2016513968A5 (enExample) | 2017-04-13 |
Family
ID=51658978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501273A Withdrawn JP2016513968A (ja) | 2013-03-11 | 2014-03-11 | Ｏ−結合ｎ−アセチルグルコサミントランスフェラーゼを標的する組成物及び方法並びに創傷治癒を促進する組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20170166897A1 (enExample) |
| EP (1) | EP2970978A4 (enExample) |
| JP (1) | JP2016513968A (enExample) |
| KR (1) | KR20150126048A (enExample) |
| CN (1) | CN105408480A (enExample) |
| AU (1) | AU2014248966A1 (enExample) |
| BR (1) | BR112015022701A2 (enExample) |
| CA (1) | CA2905337A1 (enExample) |
| CL (1) | CL2015002599A1 (enExample) |
| MX (1) | MX2015012124A (enExample) |
| RU (1) | RU2015138544A (enExample) |
| SG (1) | SG11201507211YA (enExample) |
| WO (1) | WO2014164805A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020117937A1 (en) * | 2018-12-06 | 2020-06-11 | Bio Capital Holdings, LLC | Glucose sensors and methods of use thereof |
| CN111234022B (zh) * | 2019-12-16 | 2024-03-22 | 江苏省药物研究所有限公司 | 抗n-乙酰氨基葡萄糖转移酶修饰的蛋白质单克隆抗体及杂交瘤细胞株和其制备方法与应用 |
| CN112707955B (zh) * | 2020-12-21 | 2022-01-18 | 山东润德生物科技有限公司 | 提高N-乙酰氨基葡萄糖产量的RamAM转录因子突变体 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL108367A0 (en) * | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| AU6942598A (en) * | 1997-03-31 | 1998-10-22 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | O-linked glcnac transferase (ogt): cloning, molecular expression, and methods ofuse |
| CA2333901A1 (en) * | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
| EP1621212B1 (en) * | 1999-01-27 | 2011-11-16 | Coda Therapeutics, Inc. | Formulations comprising antisense nucleotides to connexins |
| CN101356437B (zh) * | 2005-12-22 | 2012-08-01 | J-油坊株式会社 | 具有由GnT-V转移的GlcNAc的糖链的检测方法 |
| US20110257034A1 (en) * | 2008-10-10 | 2011-10-20 | Cornell University | Methods for identifying genes which predict disease outcome for patients with colon cancer |
| US20120046186A1 (en) * | 2010-08-20 | 2012-02-23 | Pelham Robert J | Gene Expression Markers for Prediction of Response to Platinum-Based Chemotherapy Drugs |
| JP2012083193A (ja) * | 2010-10-12 | 2012-04-26 | Univ Of Tokyo | ヒストンタンパク質のグリコシル化を検出するための方法、並びに当該方法に用いられる抗体 |
-
2014
- 2014-03-11 BR BR112015022701A patent/BR112015022701A2/pt not_active IP Right Cessation
- 2014-03-11 EP EP14779180.0A patent/EP2970978A4/en not_active Withdrawn
- 2014-03-11 WO PCT/US2014/023525 patent/WO2014164805A1/en not_active Ceased
- 2014-03-11 MX MX2015012124A patent/MX2015012124A/es unknown
- 2014-03-11 KR KR1020157028279A patent/KR20150126048A/ko not_active Withdrawn
- 2014-03-11 RU RU2015138544A patent/RU2015138544A/ru not_active Application Discontinuation
- 2014-03-11 US US14/774,800 patent/US20170166897A1/en not_active Abandoned
- 2014-03-11 JP JP2016501273A patent/JP2016513968A/ja not_active Withdrawn
- 2014-03-11 AU AU2014248966A patent/AU2014248966A1/en not_active Abandoned
- 2014-03-11 CN CN201480026966.0A patent/CN105408480A/zh active Pending
- 2014-03-11 SG SG11201507211YA patent/SG11201507211YA/en unknown
- 2014-03-11 CA CA2905337A patent/CA2905337A1/en not_active Abandoned
-
2015
- 2015-09-11 CL CL2015002599A patent/CL2015002599A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Brennan et al. | Emerging targets for reprograming the immune response to promote repair and recovery of function after spinal cord injury | |
| Mei et al. | Therapeutic RNA strategies for chronic obstructive pulmonary disease | |
| Li et al. | Osteopontin RNA aptamer can prevent and reverse pressure overload-induced heart failure | |
| Karras et al. | Inhibition of antigen-induced eosinophilia and late phase airway hyperresponsiveness by an IL-5 antisense oligonucleotide in mouse models of asthma | |
| Xie et al. | MicroRNA-29c prevents pulmonary fibrosis by regulating epithelial cell renewal and apoptosis | |
| JP5753838B2 (ja) | コレステロール関連障害の治療におけるｍｉｒ−３３マイクロｒｎａの調節 | |
| Nossent et al. | The 14q32 microRNA-487b targets the antiapoptotic insulin receptor substrate 1 in hypertension-induced remodeling of the aorta | |
| JP2016506240A5 (enExample) | ||
| JP2012050438A5 (enExample) | ||
| JP2017113007A5 (enExample) | ||
| JP2010539950A5 (enExample) | ||
| JP2015518373A5 (enExample) | ||
| HRP20201200T1 (hr) | OLIGONUKLEOTIDNI SPOJEVI ZA CILJANJE HUNTINGTIN mRNK | |
| JP2012041342A5 (enExample) | ||
| Horsburgh et al. | MicroRNAs in the skin: role in development, homoeostasis and regeneration | |
| JP2010512404A5 (enExample) | ||
| RU2015155332A (ru) | Олигонуклеотидные модуляторы в-клеточной cll/лимфомы 11а (bcl11а) и их применение | |
| JP2014525435A5 (enExample) | ||
| Yu et al. | Leukemia inhibitory factor attenuates renal fibrosis through Stat3-miR-29c | |
| Zhao et al. | MiR-7-5p enhances cerebral ischemia–reperfusion injury by degrading sirt1 mRNA | |
| JP2018533956A5 (enExample) | ||
| JP2016513968A5 (enExample) | ||
| Cao et al. | MicroRNA as a Potential Biomarker and Treatment Strategy for Ischemia‐Reperfusion Injury | |
| JP2020502151A5 (enExample) | ||
| Mollah | MicroRNA in fibrotic disorders: a potential target for future therapeutics |